GW Henssler & Associates Ltd. Has $22.82 Million Stock Position in IDEXX Laboratories, Inc. $IDXX

GW Henssler & Associates Ltd. reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.8% during the 4th quarter, HoldingsChannel reports. The fund owned 33,737 shares of the company’s stock after selling 2,095 shares during the quarter. IDEXX Laboratories comprises 1.1% of GW Henssler & Associates Ltd.’s investment portfolio, making the stock its 29th largest position. GW Henssler & Associates Ltd.’s holdings in IDEXX Laboratories were worth $22,824,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Virtus Advisers LLC bought a new stake in IDEXX Laboratories in the 3rd quarter valued at $26,000. Park Place Capital Corp bought a new stake in IDEXX Laboratories in the 4th quarter valued at $29,000. WealthCollab LLC bought a new stake in IDEXX Laboratories in the 2nd quarter valued at $30,000. Greykasell Wealth Strategies Inc. bought a new stake in IDEXX Laboratories in the 3rd quarter valued at $35,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in IDEXX Laboratories in the 3rd quarter valued at $36,000. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Stock Up 0.6%

IDEXX Laboratories stock opened at $566.79 on Tuesday. The stock has a market cap of $44.71 billion, a P/E ratio of 41.74, a P/E/G ratio of 3.27 and a beta of 1.56. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a twelve month low of $504.56 and a twelve month high of $769.98. The company’s 50-day moving average price is $564.32 and its two-hundred day moving average price is $635.65.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the prior year, the business posted $2.91 EPS. The business’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. BTIG Research cut their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Barclays cut their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Finally, UBS Group cut their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.